No Data
Express News | Zhaoke Ophthalmology - Nmpa Acceptance of Abbreviated New Drug- Application for Nvk002 for Treatment of- Myopia Progression in Children
Hong Kong stocks movement | ZHAOKE OPHTH-B (06622) once rose more than 8% as the drug for treating wet age-related macular degeneration reached the primary endpoint in its Phase III clinical trial.
ZHAOKE OPHTH-B (06622) once rose over 8%, as of the time of writing, it increased by 5.83%, priced at 1.27 Hong Kong dollars, with a transaction amount of 0.8308 million Hong Kong dollars.
Zhao Ke Ophthalmology (06622): TAB014 related clinical trials have yielded positive results.
Kingwo Financial News | Zhaoke Ophthalmology (06622) announced that TAB014 (one of the company's core candidate drugs) has positive topline results from the Phase III clinical trial for the treatment of wet (neovascular) age-related macular degeneration (“wAMD”). This clinical trial successfully achieved the primary endpoint and key secondary endpoints. The Phase III clinical trial of TAB014 is a randomized, double-blind, and non-inferiority study, with the main objective of assessing the best corrected visual acuity (BCVA) at week 52 for the group receiving TAB014 treatment compared to the group receiving Lucentis treatment at baseline.
Zhaoke Ophthalmology-B (06622.HK): Latanoprost eye drops, Tafluprost eye drops, and Tafluprost nasal drops have been approved for marketing by the National Medical Products Administration.
On December 9, Gelonghui reported that Zhaoke Ophthalmology-B (06622.HK) announced that following the approval for marketing of Betamethasone Timolol Eye Drops and Bimatoprost Eye Drops, the company's glaucoma product portfolio has recently added three more pharmaceuticals (Latanoprost Eye Drops, Travoprost Eye Drops, and Travoprost Timolol Eye Drops) that have been approved for listing by the National Medical Products Administration ("NMPA"), equivalent to passing the consistency evaluation of generic drugs. These pharmaceuticals are all produced by the company. Together with Betamethasone Timolol Eye Drops and Bimatoprost Eye Drops, they constitute a comprehensive glaucoma product portfolio for managing intraocular pressure. The company believes its products...
Express News | Zhaoke Ophthalmology - Marketing Authorizations Obtained From Nmpa for Latanoprost Eye Drop, Travoprost Eye Drop, and Travoprost Timolol Eye Drop
Zhaoke Ophthalmology's Phase 3 Trial of Myopia Progression Drug Shows Positive Results
No Data
